Theravance Biopharma, Inc. Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2022
February 27, 2023 at 04:05 pm EST
Share
Theravance Biopharma, Inc. reported earnings results for the fourth quarter and full year ended December 31, 2022. For the fourth quarter, the company reported revenue was USD 14.65 million compared to USD 14.95 million a year ago. Net loss was USD 10.36 million compared to USD 32.04 million a year ago. Basic loss per share from continuing operations was USD 0.21 compared to USD 0.78 a year ago. Basic loss per share was USD 0.15 compared to USD 0.43 a year ago.
For the full year, revenue was USD 51.35 million compared to USD 55.31 million a year ago. Net income was USD 872.13 million compared to net loss of USD 199.43 million a year ago. Basic loss per share from continuing operations was USD 1.26 compared to USD 3.82 a year ago. Basic earnings per share was USD 11.85 compared to basic loss per share of USD 2.87 a year ago.
Theravance Biopharma, Inc. is a biopharmaceutical company primarily focused on the development, and commercialization of medicines. Its product, YUPELRI (revefenacin) inhalation solution is indicated for the maintenance treatment of patients with chronic obstructive pulmonary disease (COPD). YUPELRI is a prescription medicine used to treat COPD, a long-term lung disease that includes chronic bronchitis, emphysema, or both. YUPELRI is an anticholinergic medicine, which helps the muscles around the airway in lungs stay relaxed to prevent symptoms, such as wheezing, shortness of breath and others. Its pipeline of internally discovered programs is targeted to address unmet patient needs. Ampreloxetine, its late-stage investigational norepinephrine reuptake inhibitor in development for symptomatic neurogenic orthostatic hypotension. Its Selective 5-HT4 Agonist (TD-8954) is a selective 5-HT4 receptor agonist, which is developed for the treatment of gastrointestinal motility disorders.
THERAVANCE BIOPHARMA, INC. 
